Stem Cell-Based Disease Models for Inborn Errors of Immunity
Cells, vol. 11, pp. 108
Abstract
The intrinsic capacity of human hematopoietic stem cells (hHSCs) to reconstitute myeloid and lymphoid lineages combined with their self-renewal capacity hold enormous promises for gene therapy as a viable treatment option for a number of immune-mediated diseases, most prominently for inborn errors of immunity (IEI). The current development of such therapies relies on disease models, both in vitro and in vivo, which allow the study of human pathophysiology in great detail. Here, we discuss the current challenges with regards to developmental origin, heterogeneity and the subsequent implications for disease modeling. We review models based on induced pluripotent stem cell technology and those relaying on use of adult hHSCs. We critically review the advantages and limitations of current models for IEI both in vitro and in vivo. We conclude that existing and future stem cell-based models are necessary tools for developing next generation therapies for IEI.
Authors 4
-
Leiden University Medical Center
Affiliation as printed
Department of Immunology, Leiden University Medical Center, 2333 ZA Leiden, The Netherlands
-
Leiden University Medical Center
Affiliation as printed
Department of Immunology, Leiden University Medical Center, 2333 ZA Leiden, The Netherlands
-
Leiden University Medical Center
Affiliation as printed
Department of Immunology, Leiden University Medical Center, 2333 ZA Leiden, The Netherlands
-
Leiden University Medical Center
Affiliation as printed
Department of Immunology, Leiden University Medical Center, 2333 ZA Leiden, The Netherlands
Cited by 1 stored of 1
1 result
No patents citing this paper on Lens.org (checked 2026-10-11).